[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335891-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335891-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","current-standards-multidisciplinary-approaches-and-future-directions-in-the-management-of-extrahepatic-cholangiocarcinoma","Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma","","Biliary tract cancers encompass anatomically and molecularly diverse diseases, including extrahepatic cholangiocarcinoma (perihilar and distal) and gallbladder cancer. Current standards for extrahepatic cholangiocarcinoma rely on definitive surgery when resectable, often followed by adjuvant chemotherapy with selective radiation or chemoradiation. For advanced disease, gemcitabine plus cisplatin remains the systemic backbone, recently strengthened by immune checkpoint blockade in TOPAZ-1 and KEYNOTE-966. The review addresses subtype-specific trial outcomes, the value of neoadjuvant strategies and molecular testing, limited second-line options, and the need for multidisciplinary, patient-centered care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/current-standards-multidisciplinary-approaches-and-future-directions-in-the-management-of-extrahepatic-cholangiocarcinoma/335891/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/current-standards-multidisciplinary-approaches-and-future-directions-in-the-management-of-extrahepatic-cholangiocarcinoma/335891.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the current standard treatment when extrahepatic cholangiocarcinoma is resectable?","Question",{"text":63,"@type":64},"When resectable, definitive surgery is followed by adjuvant chemotherapy, sometimes combined with selective radiation or chemoradiation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is advanced extrahepatic cholangiocarcinoma typically managed systemically?",{"text":68,"@type":64},"Combination gemcitabine and cisplatin remains the standard base for systemic therapy, with improved outcomes reported from adding immune checkpoint blockade to the chemotherapy doublet in TOPAZ-1 and KEYNOTE-966.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is molecular testing emphasized in extrahepatic cholangiocarcinoma care?",{"text":72,"@type":64},"Molecular testing helps detect actionable mutations, enabling targeted therapies that can improve survival in advanced-stage disease and is increasingly considered across treatment timelines.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335891,1790151358,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Current Treatment Options in Oncology (2024) 25:127–160 DOI 10.1007/s11864-023-01153-5  \nCurrent Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma  \nMargaret Wheless, MD1 Rajiv Agarwal, MD1,2 Laura Goff, MD1,2 Natalie Lockney, MD2,3  \nChandrasekhar Padmanabhan, MD2,4 Thatcher Heumann, MD, MPH1,2,*  \nAddress  \n*,1 Department of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building Suite 798, Nashville, TN 37232, USA  \nEmail: [thatcher.heumann@vumc.org](thatcher.heumann@vumc.org)  \n2Vanderbilt-Ingram Cancer Center, Nashville, TN, USA  \n3 Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA  \n4 Department of Surgery, Division of Surgical Oncology & Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA  \nPublished online: 5 January 2024  \n© The Author(s) 2023  \nKeywords Extrahepatic cholangiocarcinoma · Biliary tract cancer · Targeted therapy · Chemotherapy · Immunotherapy  \nOpinion statement  \nBiliary tract cancers are molecularly and anatomically diverse cancers which include intrahepatic cholangiocarcinoma, extrahepatic (perihilar and distal) cholangiocarcinoma, and gallbladder cancer. While recognized as distinct entities, the rarer incidence of these cancers combined with diagnostic challenges in classifying anatomic origin has resulted in clinical trials and guideline recommended strategies being generalized patients with all types of biliary tract cancer. In this review, we delve into the unique aspects, subtype-specific clinical trial outcomes, and multidisciplinary management of patients with  \nextrahepatic cholangiocarcinoma. When resectable, definitive surgery followed by adjuvant chemotherapy (sometimes with selective radiation/chemoradiation) is current standard of care. Due to high recurrence rates, there is growing interest in the use of upfront/neoadjuvant therapy to improve surgical outcomes and to downstage patients who may not initially be resectable. Select patients with perihilar cholangiocarcinoma are being successfully treated with novel approaches such as liver transplant. In the advanced disease setting, combination gemcitabine and cisplatin remains the standard base for systemic therapy and was recently improved upon with the addition of immune checkpoint blockade to the chemotherapy doublet in the recently reported TOPAZ-1 and KEYNOTE-966 trials. Second-line all-comer treatments for these patients remain limited in both options and efficacy, so clinical trial participation should be strongly considered. With increased use of molecular testing, detection of actionable mutations and opportunities to receive indicated targeted therapies are on the rise and are the most significant driver of improved survival for patients with advanced stage disease. Though these targeted therapies are currently reserved for the second or later line, future trials are looking at moving these to earlier treatment settings and use in combination with chemotherapy and immunotherapy. In addition to cross-disciplinary management with surgical, medical, and radiation oncology, patient-centered care should also include collaboration with advanced endoscopists, palliative care specialists, and nutritionists to improve global patient outcomes.  \nIntroduction  \nBiliary tract cancers (BTC) are a diverse group of pathologically distinct entities that can be further divided into intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder cancer (GBC), with the latter two of these comprising extrahepatic BTC (eBTC) . Extrahepatic CCA is further divided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) . Distal CCA includes the common bile duct and distal ducts whereas pCCA arises from the second-order bile ducts down to the cystic duct [1] . Given their heterogeneity, BTCs have unique pathophysiolog","cbCairXdK1IYGCwd","https://ap.wps.com/l/cbCairXdK1IYGCwd","pdf",912560,34,"English","# Opinion statement\n# Introduction\n# Epidemiology and prognosis","[{\"question\":\"What is the current standard treatment when extrahepatic cholangiocarcinoma is resectable?\",\"answer\":\"When resectable, definitive surgery is followed by adjuvant chemotherapy, sometimes combined with selective radiation or chemoradiation.\"},{\"question\":\"How is advanced extrahepatic cholangiocarcinoma typically managed systemically?\",\"answer\":\"Combination gemcitabine and cisplatin remains the standard base for systemic therapy, with improved outcomes reported from adding immune checkpoint blockade to the chemotherapy doublet in TOPAZ-1 and KEYNOTE-966.\"},{\"question\":\"Why is molecular testing emphasized in extrahepatic cholangiocarcinoma care?\",\"answer\":\"Molecular testing helps detect actionable mutations, enabling targeted therapies that can improve survival in advanced-stage disease and is increasingly considered across treatment timelines.\"}]","Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma | PDF",1790012751,86]